EFFICIENCY OF ADJUVANT XELOX CHEMOTHERAPY FOR PATIENTS WITH RESECTABLE GASTRIC IN RUSSIA (SINGLE INSTITUTION RETROSPECTIVE STUDY) release_qgr6zqw5gvdabgjya3lzy3qhz4

by Ivan Stilidi, Sergey Nered, Aleksey Kalinin, Olesya Rossomakhina, Anton Barchuk

Published in Voprosi onkologii by Autonomous non-profit scientific and medical organization - Questions of Oncology.

2019   Volume 65, p256-262

Abstract

Introduction. The effectiveness of the Asian regimen of adjuvant chemotherapy in patients with gastric cancer in the European population remains unclear. The aim of our study was a retrospective assessment of adjuvant chemotherapy (XELOX regimen) after radical surgery (R0) on overall survival. Methods. Database of pts with resectable gastric cancer with stage >pT3 and/or pN+ and M0, who were operated (R0) at single oncological institution during 2007-2017 was reviewed. In univariate and multivariate analyzes were included demographic characteristics, type of tumor according to Lauren, stage, type of treatment and others. Results. 396 pts were identified and 286 were available for analysis.106 (37%) pts received at least one cycle of adjuvant chemotherapy. In univariate analysis, 5OS rate was 64% [95% Cl, 52-80] и 56% [95% Cl, 48-64; p=0,21] in patients received adjuvant chemotherapy and only surgical treatment. After stratifying patients depending on the regional lymph nodes metastasis, 5OS rate in pts with pN1-3 was 69% [95% CI, 57-85] vs 47% [95% CI, 39-58; p = 0,01], respectively...
In application/xml+jats format

Archived Files and Locations

application/pdf  331.0 kB
file_rdfrzz45svg53ipbohqk26qqt4
voprosyonkologii.ru (publisher)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2019-02-01
Container Metadata
Not in DOAJ
In Keepers Registry
ISSN-L:  0507-3758
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 6c18fcd6-5079-466d-a44c-5a12e5ebabb4
API URL: JSON